Advances in approved nucleic acid drugs and lipid nanoparticle system
10.16438/j.0513-4870.2022-1101
- VernacularTitle:上市核酸药物及其脂质纳米递送载体研究进展
- Author:
Li-li CUI
;
Yong ZHANG
- Publication Type:Research Article
- Keywords:
nucleic acid;
small interfering RNA;
messenger RNA;
ionizable lipid;
lipid nanoparticles;
italic>in vitro and in vivo delivery
- From:
Acta Pharmaceutica Sinica
2023;58(4):826-833
- CountryChina
- Language:Chinese
-
Abstract:
Nucleic acids, as a next generation of biotechnology drugs, not only can fundamentally treat diseases, but also own significant platform characteristics in view of technology and production. Therefore, nucleic acid-based drugs have broad clinical applications in biomedical fields. However, nucleic acids are degradable and unstable, and have very low intracellular delivery efficiency in vitro and in vivo, which greatly limits their applications. In recent years, ionizable lipid-based lipid nanoparticles have shown promising application potentials and have been successfully applied to COVID-19 (Coronavirus Disease 2019) vaccines in clinic. Lipid nanoparticles demonstrate high in vivo delivery efficiency and good safety profile due to their unique structural and physicochemical properties, which provides many possibilities for their clinical applications for nucleic acid delivery in the future. This review focused on the characteristics of nucleic acid drugs and their delivery barriers, and discussed the approved nucleic acid drugs to illustrate the key aspects of the success of their delivery carrier system. In addition, problems to be solved in the field were highlighted.
